ACADIA Pharmaceuticals Inc. cash flow to debt ratio of 210.47% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

ACADIA Pharmaceuticals Inc.'s free cash flow has decreased 33.11% from $157.20M last year to $105.15M, signaling decreasing performance

ACADIA Pharmaceuticals Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

ACADIA Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.07 last year to 0.06 today, signaling strengthened financials

ACADIA Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

ACADIA Pharmaceuticals Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

ACADIA Pharmaceuticals Inc.'s profit margin has increased (41.33%) in the last year from 23.64% to 33.42%, signaling increasing performance

ACADIA Pharmaceuticals Inc.'s short-term assets of $1.06B exceed its short-term liabilities of $277.11M

ACADIA Pharmaceuticals Inc.'s return on assets of 21.83% is higher than the 5.00% threshold, indicating efficient asset utilization

ACADIA Pharmaceuticals Inc.'s return on equity of 32.39%, is higher than 15.00%, indicating good performance

ACADIA Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ACADIA Pharmaceuticals Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

ACADIA Pharmaceuticals Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

ACADIA Pharmaceuticals Inc. has a free cash flow yield of 2.09%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

ACADIA Pharmaceuticals Inc.'s yearly earnings has increased 72.66% since last year from $226.45M to $391.00M, signaling increasing performance

ACADIA Pharmaceuticals Inc.'s yearly revenue has increased 11.87% since last year from $957.80M to $1.07B, signaling increasing performance

ROIC 6.19% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

ACADIA Pharmaceuticals Inc.'s 3-year revenue CAGR of 27.48% is positive, indicating growing revenue over the past 3 years

ACADIA Pharmaceuticals Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

ACADIA Pharmaceuticals Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

ACADIA Pharmaceuticals Inc. has insufficient data to evaluate this check.

ACADIA Pharmaceuticals Inc. has an earnings yield of 7.54%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

ACADIA Pharmaceuticals Inc. is overvalued relative to its fair value price of 6.44 based on EBITDA multiple model

ACADIA Pharmaceuticals Inc. has an EV/EBITDA ratio of 28.31x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

ACADIA Pharmaceuticals Inc. is overvalued relative to its fair value price of -12.23 based on Earnings Fair Value model

ACADIA Pharmaceuticals Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

ACADIA Pharmaceuticals Inc. has a price-to-book ratio of 3.86x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ACADIA Pharmaceuticals Inc. has a price-to-sales ratio of 4.43x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue